XML 17 R4.htm IDEA: XBRL DOCUMENT v3.25.3
Condensed Consolidated Statements of Operations - USD ($)
$ in Thousands
 3 Months Ended 9 Months Ended
Sep. 30, 2025
Sep. 30, 2024
Sep. 30, 2025
Sep. 30, 2024
Revenue:        
Total revenue $ 100,055 $ 82,883 $ 271,419 $ 247,206
Operating expenses:        
Research and development 16,769 17,486 52,123 55,890
Sales and marketing 24,449 19,802 71,719 60,634
General and administrative 28,429 31,744 78,881 92,791
Litigation settlement expense 0 0 5,710 0
Total operating expenses 100,301 96,604 296,160 290,820
Loss from operations (246) (13,721) (24,741) (43,614)
Other income:        
Interest income, net 2,013 3,001 7,161 8,712
Other (expense) income, net (107) 283 260 (107)
Total other income 1,906 3,284 7,421 8,605
Income (loss) before income taxes 1,660 (10,437) (17,320) (35,009)
Income tax benefit (expense) 15 (200) 74 (139)
Net income (loss) $ 1,675 $ (10,637) $ (17,246) $ (35,148)
Net income (loss) per share (Note 3):        
Basic (in usd per share) $ 0.03 $ (0.20) $ (0.32) $ (0.67)
Diluted (in usd per share) $ 0.03 $ (0.20) $ (0.32) $ (0.67)
Weighted-average shares used to compute net income (loss) per share:        
Basic (in shares) 52,507,582 52,903,338 54,016,446 52,266,106
Diluted (in shares) 53,736,790 52,903,338 54,016,446 52,266,106
Testing services revenue        
Revenue:        
Total revenue $ 72,168 $ 60,807 $ 196,122 $ 185,562
Operating expenses:        
Cost of testing services, product, patient and digital solutions 14,705 13,447 45,224 41,387
Product revenue        
Revenue:        
Total revenue 12,478 10,212 35,121 29,416
Operating expenses:        
Cost of testing services, product, patient and digital solutions 5,629 6,212 16,196 17,854
Patient and digital solutions revenue        
Revenue:        
Total revenue 15,409 11,864 40,176 32,228
Operating expenses:        
Cost of testing services, product, patient and digital solutions $ 10,320 $ 7,913 $ 26,307 $ 22,264